Clinical Education Center
- No FAQs found
- ABL Kinase Domain Mutation in CML, Cell-based
- ABO Group and Rh Type
- Acid-Fast Bacillus (AFB) Identification, Sequencing and Stain, Paraffin Block
- ADAMTS13 Activity with Reflex to ADAMTS13 Inhibitor
- Alcohol Metabolites, Quantitative, Urine
- Alpha-Globin Common Mutation Analysis
- Alpha-Globin Gene Deletion or Duplication
- Alpha-Globin Gene Sequencing
- Anti-Müllerian Hormone AssessR™
- Anti-PF4 and Serotonin Release Assay (SRA) for Diagnosing Heparin-induced Thrombocytopenia/Thrombosis (HIT/HITT)
- Antiphospholipid Antibodies
- ASCVD Risk Panel with Score
- Autoimmune Epilepsy Evaluation
- Autoimmune Diseases, Tests for
- B-cell and T-cell Clonality Assays by PCR
- B-Type Natriuretic Peptide (BNP)
- BCR-ABL1 Gene Rearrangement, Quantitative PCR
- Beta-Globin Complete
- BRCAvantage®, Ashkenazi Jewish Screen
- BRCAvantage®, Rearrangements
- BRCAvantage™, Comprehensive
- BRCAvantage™, Single Site
- CDH1 Sequencing and Deletion/Duplication
- Clostridium difficile Diagnostic Testing
- C1 Inhibitor, Protein and Functional Tests
- Calreticulin (CALR) Mutation Analysis
- Carbapenem Resistant Enterobacteriaceae Culture Screen
- Cardio IQ Lipoprotein Fractionation, Ion Mobility
- Cervical Cancer, TERC, FISH
- CFvantage® Cystic Fibrosis Expanded Screen
- Chlamydia trachomatis, TMA
- Chlamydia trachomatis/Neisseria gonorrhoeae RNA, TMA
- Chromosomal Microarray, POC, ClariSure®, Oligo-SNP
- Chromosomal Microarray, Postnatal, ClariSure® Oligo-SNP
- Chromosome Analysis and AFP with Reflex to AChE, Fetal Hgb, Amniotic Fluid
- Chromosome Analysis, Amniotic Fluid
- Chromosome Analysis, Blood
- Chromosome Analysis, Blood with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Chorionic Villus Sample
- Chromosome Analysis, High Resolution
- Chromosome Analysis, High Resolution with Reflex to Postnatal, ClariSure® Oligo-SNP Array
- Chromosome Analysis, Mosaicism
- Chromosome Analysis, Neonatal Blood
- Chromosome Analysis, Sister Chromatid Exchange
- Chromosome Analysis, Tissue
- Chromosome DEB Assay for Fanconi anemia
- Chronic Lymphocytic Leukemia (CLL) - Diagnostic and Prognostic Testing
- Culture, Fungus
- Culture, Urine, Routine
- Cystic Fibrosis Screen
- Cytomegalovirus (CMV) and Epstein Barr Virus (EBV) PCR
- D-Dimer, Quantitative
- Dementia, Secondary Causes
- Dengue Virus Testing
- Diabetes Risk Panel with Score and Cardio IQ® Diabetes Risk Panel with Score
- Drug Testing, General Toxicology (Blood, Urine, or Serum)
- Drug Toxicology Alcohol Metab, QN, Oral Fluid
- Drug Toxicology Monitoring, Oral Fluid Testing
- Factor V (Leiden) Mutation Analysis
- Familial Mediterranean Fever Mutation Analysis
- First Trimester Screen, hCG
- First Trimester Screen, Hyperglycosylated hCG (h-hCG)
- FISH, Angelman
- FISH, MET Amplification
- FISH, Myeloma, 17p-, rea 14q32 with Reflexes
- FISH, Prader-Willi
- FISH, Prenatal Screen
- No FAQs found
- HCV Genotyping
- Helicobacter pylori (H pylori) Antibody Discontinuation
- Heparin, Anti-Xa
- Hepatitis B Surface Antibody, Quantitative
- Hepatitis C Antibody with Reflex to HCV RNA, PCR with Reflex to Genotype
- Hepatitis C Viral RNA Genotype 1 NS5A Drug-resistance
- Hepatitis C Viral RNA Genotype 3 NS5A Drug Resistance
- Hepatitis C Viral RNA NS3 Drug Resistance
- Hepatitis C, RNA, Quantitative, PCR
- Hereditary Cancer Panels: MYvantageTM Hereditary Comprehensive Cancer Panel and GIvantageTM Hereditary Colorectal Cancer Panel
- Hereditary Hemochromatosis DNA Mutation Analysis
- Herpes Simplex Virus (HSV) Type-Specific IgG Antibodies
- Herpes Simplex Virus Type 2 (HSV-2) IgG Inhibition, ELISA
- HIV-1 Coreceptor Tropism, Proviral DNA
- HIV-1 Coreceptor Tropism, Ultradeep Sequencing
- HIV-1 Integrase Genotype
- HIV-1/2 Antigen and Antibodies, Fourth Generation, with Reflexes
- HPV mRNA E6/E7
- Influenza A and B Antigen, Immunoassay
- Influenza Type A and B Antibodies
- Insulin, Intact, LC/MS/MS
- Integrated Screen, Part 1
- Integrated Screen, Part 2
- Intrinsic Factor Blocking Antibody
- No FAQs found
- No FAQs found
- Maternal Serum AFP
- Melanoma, BRAF V600E and V600K Mutation Analysis, THxID®
- Metanephrines, Fractionated, Free, LC/MS/MS, Plasma
- Methylenetetrahydrofolate Reductase (MTHFR), DNA Analysis
- Microalbumin (Urinary Albumin Excretion)
- Pain Management and CYP2D6/CYP2C19
- Pain Management, Naltrexone, Quantitative, Urine
- Partial Thromboplastin Time, Activated (aPTT)
- Penta Screen
- PIK3CA Mutation Analysis
- PNH with FLAER (High Sensitivity)
- Prothrombin Time with INR
- PTH, Intact and Calcium
- Streptococcus pneumoniae (Pneumococcal) Antibody Tests
- Saccharomyces cerevisiae Antibodies (ASCA) (IgG, IgA)
- Sequential Integrated Screen, Part 1
- Sequential Integrated Screen, Part 2
- Serum Integrated Screen, Part 1
- Serum Integrated Screen, Part 2
- Serum Pregnancy Tests
- Sickle Cell Screen
- Stepwise, Part 1
- Stepwise, Part 2
- SureSwab® Trichomonas vaginalis RNA, Qualitative TMA
- SureSwab®, Candidiasis, PCR
- TP53 Sequencing and Deletion/Duplication
- T4, Free
- Tamoxifen and Metabolites, LC-MS/MS
- Testosterone Testing
- Total Testosterone, LC/MS/MS
- Triple Screen
- No FAQs found
- No FAQs found
- No FAQs found
CFvantage® Cystic Fibrosis Expanded ScreenTest code(s) 92068(X)
Question 1. How is cystic fibrosis diagnosed?
Diagnosis is based on the presence of ≥1 characteristic phenotypic feature and evidence of an abnormality in cystic fibrosis transmembrane conductance regulator (CFTR) function.1 Such evidence may be based on one of the following:
- Presence of two disease-causing mutations in the CFTR gene or
- Two abnormal quantitative pilocarpine iontophoresis sweat chloride values (>60 mEq/L) or
- Transepithelial nasal potential difference (NPD) measurements characteristic of CF
Phenotypic features of CF include, but are not limited to, the following:
- Chronic sinopulmonary disease(chronic cough and sputum production, chronic wheeze and air trapping, obstructive lung disease on lung function tests, persistent colonization with pathogens commonly found in individuals with CF, chronic chest radiograph abnormalities, chronic pansinusitis, digital clubbing)
- Gastrointestinal/nutritional abnormalities(meconium ileus, rectal prolapse, malabsorption/pancreatic insufficiency, steatorrhea, hypoproteinemia, fat-soluble vitamin deficiencies, failure to thrive, distal intestinal obstructive syndrome, recurrent pancreatitis, biliary sludging, elevation of transaminases and gamma-glutamyl transferase, direct hyperbilirubinemia, chronic hepatobiliary disease)
- Obstructive azoospermia
- Salt-loss syndromes(acute salt depletion, chronic metabolic alkalosis, hyponatremic hypochloremic dehydration)
Question 2. What does a “heterozygous”, “homozygous”, or “compound heterozygous” result mean?
- Heterozygous means the individual carries one copy of a mutation on one chromosome. If the mutation is associated with a recessive disease such as cystic fibrosis (CF), these individuals are called carriers. Carriers are typically unaffected, that is, they show no symptoms of the disease.
- Homozygous means the individual carries two copies of the same mutation, one on each chromosome. If the mutation is associated with a recessive disease such as CF, these individuals are typically affected, that is, they show symptoms of the disease. However, the diagnosis is made clinically, based on clinical features and other lab studies.
- Compound heterozygous means the individual carries one copy each of two different mutations, one on each chromosome. If the mutations are associated with a recessive disease such as CF, these individuals are typically affected. However, the diagnosis is made clinically, based on clinical features and other lab studies.
Question 3. What is the next step if my patient tests positive for one CF mutation?
It depends on the indication for the CF test:
- For obstetrics and gynecology patients, guidelines recommend performing a CF screen on the male partner.2 If he is also a CF carrier, the fetus has a 25% risk of being affected with CF. Guidelines recommend offering the couple genetic counseling and prenatal testing if both partners are CF carriers.
If her male partner’s result is negative, his residual risk to be a CF carrier is reduced, and the risk that the fetus is affected with CF is also reduced. The percent risk reduction is based on ethnicity, because the CF screen sensitivity varies by ethnic group.
- For patients suspected of having CF, additional genetic testing may be considered to determine whether a second rare mutation, not detected by the standard CF screen, is present. Rare mutations in the CF gene may be detectable through two other assays. The Cystic Fibrosis Complete Rare Mutation Analysis, Entire Gene Sequence test (test code 10917X or 10919X [NY]) can detect point mutations in this gene. The Cystic Fibrosis Gene Deletion or Duplication test (test code 16080X or 16081X [NY]) can detect deletions or duplications of this gene. Please call Quest Genomics Client Services at 866-GENE-INFO to discuss the case and additional testing options.
Question 4. If my female patient carries a CF mutation, but her male partner carries a different CF mutation, is there still a risk that their offspring could be affected with CF?
Yes, the risk to offspring of this couple is 25%. CF is a recessive disease, so, when offspring inherit any two disease-causing CF mutations there is an increased risk to be affected with CF and CF-related conditions (like male infertility, for example). It does not matter if the two CF mutations are the same, or if they are different. This is due to the fact that if a child inherits a CF mutation from each parent, it means that s/he did not inherit a normal, working gene. However, since some CF mutations may be less severe and cause more mild symptoms, the exact symptoms of the child may be difficult to predict.
Question 5. How will submitting my patient’s ethnicity change the CF result/report?
Providing patient ethnicity does not change the CF result. A positive result is still positive, and a negative result is still negative, regardless of ethnicity provided. For negative results, the residual risk that your patient is still a CF carrier is provided in a table in the report, which is broken down by ethnicity. So, one can look up the residual carrier risk, by a patient’s specific ethnic group. The percent risk reduction is based on ethnicity, because the CF screen sensitivity varies by ethnic group.
Question 6. My patient has a family history of CF and has a negative CF screen result. Does this result guarantee that my patient is not a carrier of CF?
No, please call Quest Genomics Client Services at 866-GENE-INFO to discuss this case with a genetic counselor. Documentation of the specific CF mutations in the family will be necessary to determine the accuracy of the testing that was performed on your patient.
Question 7. My patient has a clinical diagnosis of CF, but the CF screen performed was negative. What should I do next?
For patients with a clinical diagnosis of CF, additional genetic testing may be considered to determine whether rare mutations, not detected by this CF screen, are present. Rare mutations can be detected using two other assays. The Cystic Fibrosis Complete Rare Mutation Analysis, Entire Gene Sequence test (test code 10917X or 10919X [NY]) can detect point mutations in this gene. The Cystic Fibrosis Gene Deletion or Duplication test (test code 16080X or 16081X [NY]) can detect deletions or duplications of this gene. Please call Quest Genomics Client Services at 866-GENE-INFO to discuss the case and additional testing options.
Question 8. This test screens for more than 78 CF mutations, so why are the detection rates and residual risk estimates based on a subset of 78 mutations?
Detection rates and residual risk estimates are based on only 78 mutations, because the mutation frequency in all ethnic groups is currently known for only these 78 mutations. Mutation frequency in the ethnic group is required to calculate the ethnic-specific detection rate and residual carrier risk.
Frequency data in all ethnic groups is lacking for the additional mutations detected. However, these less-frequent mutations have been included in the screen because they are all associated with a clinical diagnosis of CF.
- CFTR-Related Disorders. GeneReviews. U.S. National Library of Medicine, National Institutes of Health website. http://www.ncbi.nlm.nih.gov/books/NBK1250/. Accessed June 14, 2016.
- American College of Obstetricians and Gynecologists Committee on Genetics. ACOG Committee Opinion No. 486: Update on carrier screening for cystic fibrosis. Obstet Gynecol. 2011;117:1028-1031.